YOLFTbeta
Nyrada Inc

Nyrada Inc

NYR · AU · Healthcare / Biotechnology

0.505AUD-0.01 (-1.94%)

Price History

Full chart

Market Stats

Previous Close0.515
Open0.515
Day Range0.50 – 0.515
52-Week Range0.29 – 1.44
Volume108.00K
Market Cap138.39M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.03
Dividend Yield0.00%
Beta1.03
50-Day Avg0.6762
200-Day Avg0.651

About

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. James Bonnar
  • Employees0
  • HeadquartersSalesforce Tower, Sydney Place, Sydney, NSW, Australia, 2000, Australia
  • Websitehttps://www.nyrada.com

Leadership

  • Mr. James BonnarCEO, MD & Director
  • Mr. Cameron Peter Jones C.A.Chief Financial Officer
  • Mr. Benjamin Evison Ph.D.Chief Scientific Officer
  • Mr. Dimitri BurshteinInvestor Relations Manager
  • Mr. Mark Waring B.Sc., P.M.P.Senior Vice President of US Operations
  • Mr. David James Franks BEc, C.A., F Fin, J.P.Company Secretary · b. 1970
  • Jasneet ParmarDirector of Research & Development
  • Dr. Alex SuchowerskaDirector of Clinical Development & Regulatory Affairs

Financials

Income Statement

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue4.09K486.34K1.13M2.34M1.09M1.43M3.24M2.40M-
Growth (%)-+11790.90%+131.41%+107.57%-53.18%+30.73%+126.72%-26.07%-
Cost of Revenue1191.41K1.48K1.80K4.75K6.56K2.03M4.38M3.20K
Gross Profit-119484.93K1.12M2.33M1.09M1.42M-813.91K-1.98M-3.20K
Gross Margin-2.91%99.71%99.87%99.92%99.57%99.54%-25.11%-82.59%-
Operating Expense2.15M4.39M7.66M7.94M5.95M15.51M3.75M7.22M8.57M
Operating Income-2.15M-3.90M-6.54M-5.60M-4.86M-14.08M-4.56M-9.20M-8.57M
Operating Margin-52668.95%-802.40%-581.06%-239.87%-444.53%-985.00%-140.67%-383.90%-
EBITDA-2.18M-3.44M-5.63M-3.52M-5.02M-9.25M-4.60M-5.00M-8.57M
EBITDA Margin-53348.53%-707.85%-500.42%-150.87%-459.03%-646.62%-141.77%-208.78%-
Net Income-2.42M-4.09M-5.77M-3.53M-3.97M-7.82M-1.39M-4.85M-6.53M
Net Income Margin-59077.65%-841.97%-513.03%-150.95%-363.28%-546.63%-42.76%-202.18%-
R&D689.52K1.04M1.40M2.17M1.84M6.44M2.02M4.38M3.20M
R&D as % of Total Revenue16858.68%214.07%124.40%92.77%168.36%450.36%62.40%182.59%-
Interest Expense238.30K650.85K140.35K5.61K1.39K----
Interest Expense % of Total Revenue5826.31%133.83%12.47%0.24%0.13%----

Balance Sheet

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets3.17M1.14M6.27M15.16M12.01M5.16M5.91M5.30M10.42M
Total Liabilities4.53M6.10M740.67K665.38K515.48K906.28K855.63K1.72M877.29K
Total Equity-1.36M-4.95M5.53M14.49M11.50M4.26M5.05M3.58M9.54M
Cash3.11M1.10M5.15M13.75M10.82M3.71M4.77M2.93M8.38M
Total Debt3.28M3.93M342.32K------
Net Debt171.25K2.83M-4.80M-13.75M-10.82M-3.71M-4.77M-2.93M-8.38M

Cash Flow

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-690.18K-2.01M-4.41M-2.77M-2.93M-7.23M-766.29K-5.05M-4.49M
Investing Cash Flow-4.82K-440.96-3.00K-5.00K-4.77K000-9.80K
Financing Cash Flow3.80M8.48M8.48M11.34M-268.96K01.83M3.19M9.96M
Capital Expenditure4.82K440.963.00K5.00K4.77K4.863.7609.80K
Free Cash Flow-695.00K-2.01M-4.41M-2.78M-2.94M-7.23M-766.29K-5.05M-4.50M
Dividends Paid--1.72M11.29M-----
FCF to OCF100.70%100.02%100.07%100.18%100.16%100.00%100.00%100.00%100.22%
Dividend Paid to FCF---38.96%-406.57%-----

Earnings

Report DateJan 14, 2020Aug 30, 2020Feb 21, 2021Aug 30, 2021Feb 25, 2022Aug 29, 2022Feb 24, 2023Feb 18, 2025Aug 20, 2025
EPS Estimate0.000.000.00-0.00--0.00-
EPS Actual-0.01-0.03-0.02-0.01-0.02-0.01-0.02-0.01-0.01
Surprise---------
Timing-----After-hoursAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap138.39M
Enterprise Value122.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales68.81
Price / Book12.84
EPS-0.03
Book Value0.039
Revenue (TTM)2.01M
Gross Profit (TTM)-1.20M
EBITDA-6.74M
Profit Margin0.00%
Operating Margin-284.04%
Return on Equity-99.95%
Return on Assets-53.59%
Shares Outstanding258.68M
Shares Float125.88M
Beta1.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%